4.1 Article

Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities

期刊

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE
卷 5, 期 3, 页码 183-188

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsptsci.2c00016

关键词

trace amines; antipsychotics; ulotaront; molecular dynamics; treatment-resistant schizophrenia; depression

向作者/读者索取更多资源

Schizophrenia is a complex and severe mental illness. Current treatments primarily target dopamine neurotransmission and have limited effects on negative symptoms and cognitive impairments. Recent research on trace amine associated receptor-1 (TAAR1) suggests it may be a promising nondopaminergic target for treating schizophrenia and related disorders, with fewer side effects.
Schizophrenia is a complex and severe mental illness. Current treatments for schizophrenia typically modulate dopaminergic neurotransmission by D2-receptor blockade. While reducing positive symptoms of schizophrenia, current antipsychotic drugs have little clinical effect on negative symptoms and cognitive impairments. For the last few decades, discovery efforts have sought nondopaminergic compounds with the aim to effectively treat the broad symptoms of schizophrenia. In this viewpoint, we provide an overview on trace amine associated receptor-1 (TAAR1), which presents a clinically validated nondopaminergic target for treating schizophrenia and related disorders, with significantly less overall side-effect burden. TAAR1 agonists may also be specifically beneficial for the substance abuse comorbidity and metabolic syndrome that is often present in patients with schizophrenia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据